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Summary
Background and purpose: The majority of heart transplant (HTx) candidates require left ven-Complications; tricular assist device (LVAD) support for more than 2 years before transplantation in Japan.Heart failure;
Treatment;
Stroke;
Transplantation
However, the only currently available device is the extracorporeal pulsatile LVAD. The long-
term management of extracorporeal LVAD support has improved remarkably over the years. To
determine which post-operative management factors are related to the long-term survival of
patients on such LVAD, we retrospectively compared the incidence of complications and their
management strategies between the initial and recent eras of LVAD use, classiﬁed by the year
of LVAD surgery.
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Methods: Sixty-nine consecutive patients supported by extracorporeal pulsatile LVAD as a bridge
to HTx between 1994 and 2007 were reviewed retrospectively. The patients were assigned accord-
ing to the time of LVAD surgery to either group A (n = 30; between 1994 and 2000) or group B (n = 39;
between 2001 and 2007).
Results: Patients in group B survived signiﬁcantly longer on LVAD support than those in group
A (674.6 vs. 369.3 days; p < 0.001). The 1- and 2-year survival rates were signiﬁcantly higher in
group B than that in group A (82% vs. 48%, p < 0.0001; 68% vs. 23%, p < 0.0001, respectively). The
proportion of deaths due to cerebrovascular accidents was lower (17% vs. 50%, p < 0.001) in group
B compared with group A. The incidences of systemic infection were similar in both groups, but
the proportions of patients alive and achieving transplant surgery after systemic infection were
higher in group B than those in group A (55% vs. 14%, p < 0.01; 14% vs. 36%, p < 0.05, respectively).
Conclusions: The long-term survival of patients even on ‘‘ﬁrst-generation’’ extracorporeal LVAD
has improved signiﬁcantly in the recent era. Careful management of cerebrovascular accidents
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time-international normalized ratio (INR) range of 3—4 [15].
All patients received pre- and peri-operative prophylactic
antibiotic treatment with vancomycin and aztreonam.and systemic infection will p
© 2010 Japanese College of C
Introduction
Heart transplantation provides considerable survival ben-
eﬁts for patients with end-stage heart failure, but it is
available for only a small fraction of such patients [1] due
to donor shortage [2]. Therefore, most patients on the
heart transplant waiting list require long-term support by
a left ventricular assist device (LVAD). Only 60 heart trans-
plants have been performed over the past 10 years in Japan.
Therefore, the mean waiting period of Japanese transplant
candidates after LVAD surgery often exceeds 2 years and
occasionally reaches 4 years [3].
However, the ‘‘ﬁrst-generation’’ pulsatile extracorporeal
LVAD (Toyobo-LVAS®; Toyobo-National Cardiovascular Cen-
ter, Osaka, Japan) is the only type of LVAD covered by the
National Health Insurance System in Japan, and implantable
LVADs have not yet been approved for coverage. Next gener-
ation devices such as the HeartMate XVE® (Thoratec Corp.,
Pleasanton, CA, USA, and Texas Heart Institute, Houston, TX,
USA) and Norvacor® (World Heart, Inc., Oakland, CA, USA)
have completed clinical trials in Japan and are now under-
going review and approval by the Ministry of Health, Labor
and Welfare [4—6]. A new rotary pump device is also under
review [7].
Extracorporeal LVAD was primarily designed for short-
term support, but it is used in Japan over the long term as
a ‘bridge-to-transplant’ device. Patients supported by pul-
satile extracorporeal LVAD cannot be discharged from the
hospital, and cannot leave the intensive care ward without
attendant medical doctors. Thus, the use of LVAD as a ‘des-
tination therapy’ has not yet been approved by the Ministry
of Health, Labor and Welfare. This means that transplant
candidates supported by LVAD in Japan must remain in the
intensive care ward for more than 2 years before receiving
a transplant, except when undergoing cardiac rehabilitation
outside the ward. Since patients supported by extracorpo-
real LVAD were not eligible for taking a shower or a bath,
Higashi et al. [8] applied appendicular thermal therapy to
one patient and reported that the therapy was safe, atten-
uated psychological and physical stress of the patient, and
had the potential of improving cardiac function.
As a result of the recent advances in the management
techniques for pulsatile extracorporeal LVAS, the survival
rate and transplant rate of patients supported by pulsatile
t
a
p
uportant roles in the long-term LVAD management.
ology. Published by Elsevier Ireland Ltd. All rights reserved.
xtracorporeal LVAS have improved considerably [9]. To
ccomplish long-term pulsatile extracorporeal LVAD support,
etailed observations as well as rapid responses to LVAD-
elated complications are essential. The REMATCH study
5,10] showed that sepsis is the leading cause of death
29.5%) after LVAD surgery while cerebrovascular accidents
CVA) are the third cause of death (9.0%). The present
tudy focused on CVA and infection as major complica-
ions in patients supported by pulsatile extracorporeal LVAD
n Japan, and investigated the current responses to such
omplications. Although only one type of pulsatile extra-
orporeal VAD (Toyobo-VAS®) is available in Japan, we
peculate that the recent management techniques and the
esponses to pulsatile extracorporeal LVAD-related compli-
ations investigated in this study would also be useful for
anaging other types of LVAD such as the axial ﬂow types
11—14].
ethods
atients and study design
e retrospectively reviewed 69 consecutive patients at our
nstitution who were supported by pulsatile extracorpo-
eal VAD (Toyobo-VAS®) as a bridge to heart transplantation
etween April 1994 and March 2007. Patients supported
y LVAD as a bridge to recovery and/or rescue therapy
or surgical complications, acute myocarditis, or acute
nset of extensive coronary artery occlusion were excluded
rom this study. To investigate how management tech-
iques have changed over time, patients were assigned to
wo groups according to the time of LVAD surgery. Thirty
atients who had LVAD surgery between 1994 and 2000
ere assigned to group A, and 39 patients who underwent
urgery between 2001 and 2007 were assigned to group B.
ll patients received warfarin with a target prothrombinOverall survival after LVAD surgery, eligibility for heart
ransplant, duration of support, and complications and man-
gements were compared between the two groups. All the
atients provided written informed consent with regard to
se of the pulsatile extracorporeal device. The present study
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Table 1 Demographic and clinical characteristics of patients.
Parameter Group A (n = 30) Group B (n = 39) p-Value
Age at LVAD implantation (y) 35.1± 14.7 33.9± 10.8 0.697
Male (%) 15(50%) 19(50%) 0.891
Reason for LVAD implantation (no. of patients, %)
Dilated cardiomyopathy 25 (83.3%) 31 (79.5%) 0.924
Dilated phase hypertrophic cardiomyopathy 3 (10.0%) 3 (7.7%) 0.925
Ischemic cardiomyopathy 1 (0.3%) 2 (5.1%) 0.816
Others 1 (0.3%) 3 (7.7%) 0.804
Treatment at time of LVAD surgery (no. of patients, %)
Ventilator 12 (40.0%) 15 (38.4%) 0.901
IABP 8 (26.7%) 10 (25.6%) 0.857
PCPS 2 (6.6%) 3 (7.7%) 0.760
Continuous intravenous inotropic agents 30(100%) 39(100%) —
Warfarin 9 (30.0%) 12 (30.8%) 0.845
Aspirin 13 (43.3%) 15 (38.5%) 0.871
Diuretic 30(100%) 39(100%) —
-Blockers 6 (20.0%) 8 (42.1%) 0.803
ACE inhibitors or A-II antagonists 12 (40.0%) 14 (35.9%) 0.922
Hemodynamic variables within 5 days from LVAD surgery
CI (Lmin−1 m−2) 2.1± 0.5 2.1± 0.4 0.852
PAWP (mmHg) 25.0± 8.9 27.9± 10.6 0.345
Mean PA (mmHg) 29.7± 10.6 32.6± 9.6 0.367
Mean RA (mmHg) 11.3± 6.3 10.7± 6.8 0.764
Laboratory data within 5 days from LVAD surgery
TP (g/dL) 6.5± 0.2 6.3± 0.2 0.422
T-Bil (mg/dL) 2.9± 0.4 2.0± 0.4 0.111
BUN (mg/dL) 26.9± 4.0 38.7± 3.67 0.034
Cre (mg/dL) 1.2± 0.2 1.8± 0.2 0.016
BNP (pg/mL) 738.7± 197.6 1436.5± 178.8 0.011
Inﬂow cannula drainage site
Left atrium drainage 14 (46.7%) 1(2.6%) <0.0001
Left ventricular drainage 16 (53.3%) 38 (97.4%) <0.0001
LVAD, left ventricular assist device; IABP, intra aortic balloon pumping; PCPS, percutaneous cardiopulmonary support; ACE, angiotensin-
converting enzyme; A-II, angiotensin II; CI, cardiac index; PAWP, pulmonary arterial wedge pressure; PA, pulmonary artery pressure; RA,
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as approved by the Institutional Review Board and the
nstitutional Ethical Committee for Human Research at the
ational Cardiovascular Center, and conducted according to
he Declaration of Helsinki.
tatistical analysis
ata are presented as means± SD. Normality was evalu-
ted for each variable on the basis of normal distribution
lots and histograms and by the Kolmogorov—Smirnov test.
linical characteristics, duration and outcome after LVAD
urgery, and complications were compared between groups
sing Student’s unpaired two-tailed t-test or chi-square
nalysis. Survival after LVAD surgery was compared using the
aplan—Meier analysis and log rank statistics. All statistical
nalyses were performed using the JMP 7.0 software (SAS
nstitute, Cary, NC, USA).
t
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gd urea nitrogen; Cre, creatinine; BNP, brain natriuretic peptide.
esults
upport duration and prognosis
able 1 summarizes the demographic and clinical data
n groups A and B. Age and gender distribution did not
iffer between groups A and B. The proﬁles of mechan-
cal support and/or drug administration at the time of
VAD surgery also did not differ signiﬁcantly between the
wo groups. Hemodynamic variables obtained by pulmonary
rtery catheterization within 5 days prior to LVAD surgery
r at the time of operation were not signiﬁcantly differ-
nt between the groups. Nutritive status as reﬂected by
otal serum protein was not different, either. Although liver
unction as indicated by total bilirubin was not signiﬁcantly
ifferent, the indexes of renal function such as serum urea
itrogen and creatinine level were signiﬁcantly elevated in
roup B compared with group A. Serum concentration of
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Table 2 Outcome after left ventricular assist device surgery.
Parameter Group A (n = 30) Group B (n = 39) p-Value
Duration of LVAD support (days) 369.3± 337.2 674.6± 321.3 0.0003
Outcome (no. of patients, %)
Transplanted in Japan 6 (20.0%) 11 (28.2%) 0.615
Transferred and transplanted outside Japana 2 (6.6%) 4 (10.2%) 0.925
Died 22 (73.3%) 14 (35.9%) 0.005
Remaining on waiting list 0(0%) 10 (25.6%) 0.007
a A number of transplant candidates were transferred and underwent heart transplantation outside Japan, due to extreme donor
shortage and legal constraints in Japan. Japanese organ transplant law did not have criteria for the diagnosis of brain death for those
aged under 15 years, thus, pediatric patients had no chance of receiving heart transplant surgery in Japan.
Figure 1 Outcome of transplant candidates after left ventricular
panel).
brain natriuretic peptide (BNP) was higher in group B than
that in group A. The site of inﬂow cannula drainage was dis-
tinctly different between groups A and B. Fourteen patients
(46.7%) underwent LVAD implantation with left atrium inﬂow
cannula drainage in group A compared with only one patient
(2.6%) in group B.
Table 2 and Fig. 1 summarize the outcomes of patients
in groups A and B. The duration of LVAD support was signiﬁ-
cantly longer in group B than that in group A. Mortality was
Figure 2 Kaplan—Meier’s survival curves of patients sup-
ported by extracorporeal pulsatile left ventricular assist device
(LVAD). Survival rates of groups A and B at 100 days, 1 and 2
years after LVAD surgery. Solid line and closed squares, group A;
dotted line and open squares, group B.
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cassist device surgery in group A (left panel) and group B (right
igniﬁcantly higher in group A than in group B, and none
f the patients in group A were still on the waiting list.
ig. 2 shows the Kaplan—Meier survival curves of the two
roups. Survival after LVAD surgery was signiﬁcantly lower in
roup A than in group B. The survival rate after LVAD surgery
n group B was satisfactory compared to that reported for
he post-REMATCH era [8,16,17], although our patients were
upported by LVAD as a bridge to transplant, and not as a
estination therapy.
Fig. 3 shows the causes of death in groups A and B. The
roportion of deaths due to CVA was signiﬁcantly higher in
roup A than in group B (50% vs. 13%, p < 0.0001), whereas
hat of infection did not differ signiﬁcantly between the
wo groups. The proportion of deaths due to right ven-
ricular failure, deﬁned as fatal liver or renal insufﬁciency
nder LVAD support and requirement of inotropic agents, was
igher in group B (Fig. 3).
VA after pulsatile extracorporeal LVAD
mong the 69 patients studied, 37 patients developed
VA after pulsatile extracorporeal LVAD. In this study,
VA was used as a collective term, comprising intracra-
ial hemorrhage and intracranial infarction. The incidence
nd outcome after CVA in the patients are summarized in
able 3. Rapid reversal of warfarin-induced anticoagulation
as attempted in all patients who developed intracerebral
emorrhage [15]. Vitamin K was never used in either group
f patients. Prothrombin complex concentrate (PCC), which
ontains a high level of vitamin K-dependent coagulation
224 T. Sasaoka et al.
Figure 3 Causes of death in group A (left panel) and group B (right panel). RV, right ventricular.
Table 3 Incidence of cerebrovascular accidents.
Parameter Group A (n = 30) Group B (n = 39) p-Value
Incidence of CVA (no. of patients, %) 17 (56.7%) 20 (51.2%) 0.841
Intracranial hemorrhage (no. of patients, %) 16 (53.3%) 18 (46.1%) 0.727
Intracranial infarction (no. of patients, %) 13 (43.3%) 12 (30.7%) 0.410
Anticoagulant status
Baseline INR at stable situation 3.2± 1.5 3.3± 1.2 0.759
INR on the day of CVA event 3.8± 2.1 3.2± 1.3 0.149
Among patients developed CVA
Proportion of CVA requiring neurosurgery (no. of patients, %) 12/17(70.6%) 8/20 (40.0%) 0.062
11/17(64.7%) 3/20 (15.0%) 0.006
3/17 (17.6%) 12/20 (60.0%) 0.023
o; PCC, prothrombin complex concentrate.
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Figure 4 Subgroup analysis of the Kaplan—Meier survival
curves of patients who developed cerebrovascular accident
(CVA) (group A, n = 17 vs. group B, n = 21) after extracorporeal
pulsatile left ventricular assist device (LVAD) surgery. Survival
r
i
s
pProportion of CVA leading to death (no. of patients, %)
Proportion of patients given PCC (no. of patients, %)
CVA, cerebrovascular accident; INR, international normalized rati
actors II, VII, IX and X, rapidly and effectively reverses
arfarin-induced anticoagulation [15,18—20]. This product
PPSB-HT®; Nihon Pharmaceuticals, Tokyo, Japan) has been
vailable since 2001, and it has been used at our institution
or emergency reversal of warfarin-induced anticoagulation
n cases of intracranial bleeding, intraabdominal hemor-
hage, and cardiac tamponade [15].
The majority of patients in both groups who developed
VA had a combination of intracranial hemorrhage and
ntracranial infarction as shown in Table 3, and the fre-
uencies of infarction and hemorrhage were not signiﬁcantly
ifferent between the two groups.
Neither the incidence of CVA nor the proportion of CVA
hich required subsequent neurosurgery differed signiﬁ-
antly between the two groups. However, the proportion of
atients in which CVA led to death was signiﬁcantly higher in
roup A than in group B. Fig. 4 shows the Kaplan—Meier sur-
ival curves of patients who developed CVA in both groups.
he survival rates of patients with CVA episodes were signif-
cantly lower in group A than in group B.
The proportion of patients treated with PCC after CVA
as signiﬁcantly higher in group B than in group A. To inves-
igate the effect of PCC on the prognosis of patients who
eveloped CVA, the Kaplan—Meier survival curves of patients
ho developed CVA and treated with or without adminis-
ration of PCC are shown in Fig. 5. Survival rates tended
o be better among patients treated with PCC than those
ho were not treated with PCC, but the beneﬁt of PCC for
urvival outcome was not statistically proven.
I
A
tates at 100 days, 1 and 2 years after LVAD surgery, of patients
n groups A and B who developed CVA. Solid line and closed
quares, patients in group A; dotted line and open squares,
atients in group B.nfection after pulsatile extracorporeal LVAD
mong the 69 patients studied, 53 patients developed sys-
emic infection (SI) after pulsatile extracorporeal LVAD. SI
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Table 4 Incidence of systemic infection (SI).
Parameter Group A (n = 30) Group B (n = 39) p-Value
Incidence of SI (no. of patients, %) 22 (73.3%) 31 (79.5%) 0.754
Among patients who developed SI
Proportion of SI leading to death (no. of patients, %) 4/22 (18.2%) 5/31 (16.1%) 0.861
Proportion of patients presently alive (no. of patients, %) 3/22 (13.6%) 17/31 (54.8%) 0.006
Proportion of patients undergoing transplants (no. of patients, %) 3/22 (13.6%) 11/31 (35.5%) 0.049
Cumulative number of SI episodes (cumulative no. of episodes) 76 102 -
Number of episodes per year per patient 1.2± 0.3 1.3± 0.2 0.240
SI, systemic infection deﬁned as positive blood culture when patients developed any symptoms of infection.
Figure 5 Subgroup analysis of the Kaplan—Meier survival
curves of patients who developed cerebrovascular accident
(CVA) after extracorporeal pulsatile left ventricular assist
device (LVAD) surgery and were treated with prothrombin com-
plex concentrate (PCC) (n = 22) or not treated with PCC (n = 15).
Survival rates at 100 days, 1 and 2 years after LVAD surgery, of
PCC-treated and non-PCC-treated patients. Solid line and closed
Staphylococcus aureus (MSSA) was signiﬁcantly higher in
group B than in group A. However, the proportion of
other organisms including methicillin-resistant Staphylo-
coccus aureus (MRSA) did not differ signiﬁcantly between
two groups. Linezolid is a powerful synthetic oxazolidinone
antibiotic against Gram-positive pathogens that produce
toxins [21]. It is commonly used to combat severe infection
with staphylococci including MRSA. Linezolid has been avail-
able at our institution since 2001, and has been administered
to patients with recurrent refractory MRSA or MSSA infection
under all treatment modalities. To date, 7 of our patients
were treated with linezolid, comprising 2 patients in group
A and 5 patients in group B. All of the 7 patients treated
with linezolid had more than 3 episodes of MRSA or MSSA
infection with blood culture positive, in spite of intense
antibiotic treatment. Then, we decide to use linezolid under
diagnosis of refractory staphylococcal infection. To investi-
gate the effect of linezolid on the prognosis of patients who
developed SI with recurrent MRSA or MSSA infection, the
survival rates of patients treated with and without linezolid
were compared (Fig. 6). A total of 25 patients had refrac-
tory SI with MRSA or MSSA. Among them, the survival rate of
patients who were treated with linezolid tended to be bet-
ter than those treated without linezolid, but the difference
did not reach statistical signiﬁcance.
Table 5 Strains isolated from blood cultures.
Strain Group A
(n = 30)
Group B
(n = 39)
MSSA* 2% 17%
MRSA 20% 25%
Staphylococcus epidermidis 15% 8%
Streptococcus viridans 2% 0%
Staphylococcus capitis 11% 2%
Streptococcus agalactiae 2% 0%
Staphylococcus lugdunensis 7% 6%
Enterobacter aerogenes 2% 0%
Pseudomonas aeruginosa 6% 3%
Stenotrophomonas maltophilia 0% 1%squares, patients not treated with PCC; dotted line and open
squares, patients treated with PCC.
was deﬁned as a positive blood culture when patients devel-
oped any symptom of infection. Table 4 summarizes the
incidence of SI among the patients studied. Neither the inci-
dence of patients who developed SI nor the proportion of
SI leading to death differed signiﬁcantly between the two
groups. In addition, the cumulative number of SI episodes
and the number of SI episodes per year per patient were
not signiﬁcantly different between the two groups. How-
ever, although SI itself was not a direct cause of death, a
subgroup analysis of patients with a history of SI revealed
that the proportion of patients who were alive, including
those who received transplant and those who remained on
LVAD support, was signiﬁcantly lower in group A than in group
B. The proportion of patients with a history of SI who could
undergo transplantation was signiﬁcantly lower in group A
than in group B. The duration from infection to death in
patients with a history of SI after LVAD surgery was signiﬁ-
cantly shorter in group A than in group B (256.0± 203.1 vs.
749.7± 328.8 days, p < 0.01).
Table 5 shows the strains isolated from blood cultures in
groups A and B. The proportion of methicillin-susceptible
Others 33% 42%
MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-sensitive Staphylococcus aureus.
* p < 0.0001.
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Figure 6 Subgroup analysis of the Kaplan—Meier survival
curves of patients who developed systemic infection (SI)
with methicillin-resistant Staphylococcus aureus (MRSA) or
methicillin-sensitive Staphylococcus aureus (MSSA) after extra-
corporeal pulsatile left ventricular assist device (LVAD) surgery,
and who were treated with linezolid (LZD) (n = 7) or not treated
with linezolid (n = 18). Survival rates at 100 days, 1 and 2
years after LVAD surgery, of linezolid-treated and non-linezolid-
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areated patients. Solid line and closed squares, patients not
reated with linezolid; dotted line and open squares, patients
reated with linezolid.
iscussion
e found that even the ﬁrst generational extracorporeal
VAD can achieve sufﬁcient long-term support. Extracorpo-
eal LVAD has been withdrawn as the ﬁrst-line mechanical
irculatory support worldwide, and its use is limited to short-
erm support or for pediatric patients [22—24]. However,
t is currently the only device that is ofﬁcially approved in
apan by the National Health Insurance System, therefore
atients with severe heart failure who need LVAD as a bridge
o transplant have no other choice at present.
Several studies have investigated the feasibility of long-
erm LVAD usage, but all of them examined implantable
evices [9,16,17,25]. To the best of our knowledge, this
s the ﬁrst study to investigate the outcomes of long-term
upport with pulsatile extracorporeal LVAD and the compli-
ations in using such type of LVAD. We found that pulsatile
xtracorporeal LVAD can support patients for an average of
60 days (including patients with ongoing support). This ﬁnd-
ng is equal or superior to that reported in the post-REMATCH
ra, even considering the difference in the proportion of
atients.
The present study found that survival outcome has
mproved dramatically over the past 8 years even though the
robability of complications did not differ. The improvement
ight be associated with progress in careful and prompt
anagement for complications. The important impediments
o long-term LVAD support are CVA, infections, and right
eart failure [11,26,27]. Although the incidence of CVA did
ot differ signiﬁcantly, the number of patients who died of
VA has recently become appreciably lower. The incidence
f SI has not changed, but the management of patients who
ecome systemically infected has improved signiﬁcantly.
n the present study, we speculated that these improve-
z
t
m
o
tT. Sasaoka et al.
ents might be associated with prompt administration of
CC for CVA and well-selected administration of linezolid
or staphylococcus-related SI.
We used the term CVA collectively for both cerebral hem-
rrhage and cerebral infarction. The prognosis is generally
xpected to be worse for cerebral hemorrhage than cere-
ral infarction, and PCC was used only in patients with
emorrhage in this study. However, most patients devel-
ped cerebral hemorrhage after infarction, and 90% or
ore of the patients with CVA in both groups had cere-
ral hemorrhage (Table 3). Therefore, we analyzed cerebral
emorrhage and infarction together under the broad term
VA. Nevertheless, this might have limited to some extent
he analysis of the effectiveness of PCC in managing patients
ith CVA. In the present study, the use of PCC did not signif-
cantly improve the prognosis of patients with CVA (Fig. 5);
owever, other studies [15,19,28,29] have shown that PCC
s effective against intracranial hemorrhage. Indeed, we
ecently reported that the proportion of patients’ survival
n LVAD after intracranial hemorrhage events was signiﬁ-
antly increased when treated with PCC compared to that
hen treated without PCC administration [15]. Huttner et
l. [28] have shown that the incidence of hematoma growth
s signiﬁcantly lower in patients with warfarin-associated
ntracranial hemorrhage who received PCC than in those who
id not. Further studies are needed to evaluate the efﬁcacy
f PCC to prevent fatal intracranial hematoma growth in
atients supported by LVAD who developed CVA.
Although a high frequency of side effects has limited its
se, linezolid is reported to be superior to vancomycin for
reating MRSA infection [30,31]. In addition, linezolid is a
owerful drug to treat severe infections by not only MRSA,
ut also other Gram-positive bacteria, even in peculiar
natomical sites in which therapeutic levels of antibiotics
annot be achieved [32]. Falagas et al. [33] reviewed
he literature and reported the effectiveness of linezolid
or endocarditis due to multidrug-resistant Gram-positive
occi. Coagulase negative staphylococci and Staphylococ-
us aureus have been reported to be the most common
athogens in LVAD-related infections [34]. Indeed, as shown
n Table 5, most of our patients who had SI were infected
y Gram-positive pathogens. Therefore, linezolid might be
useful antibiotic agent for treating the most common
esponsible pathogens in LVAD patients.
We failed to demonstrate statistically the contribution
f linezolid in improving the survival of patients with LVAD-
elated MRSA or MSSA infectious, and the number of the
atients treated with linezolid in this study was too small to
rove the effectiveness of linezolid. However, all patients
ith MRSA or MSSA related SI who were treated with line-
olid could survive more than 600 days on LVAD, whereas
hose not treated with linezolid tended to show poorer
urvival (Fig. 6). Although we do not have an institu-
ional protocol of linezolid administration, we used linezolid
nly in patients with refractory staphylococcal infection,
nd the conditions of patients treated with linezolid are
ssumed to be severer than those not treated with line-
olid. Further prospective studies are needed to validate
he superiority of linezolid use over existing antibiotic regi-
ens, and to establish the appropriate dosage and regimen
f this drug for these patients. Although not observed in
his study, linezolid-resistant Staphylococcus is becoming
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a recent concern in severe SI [35], which requires careful
observation.
One of the limitations of this study was that we did
not identify the causes of infections, which vary depend-
ing on the duration after LVAD implantation. In the acute
phase, infectious complications may be related to preoper-
ative condition, and/or surgical intervention. In the chronic
phase, they are mostly due to infection of exit sites of
inﬂow and/or outﬂow cannulae. Driveline infections may
require surgical debridement [36]. LVAD-associated endo-
carditis and bacteremia may relapse after prolonged courses
of antibiotics [37]. Although heart transplantation could
cure LVAD-related endocarditis by removal of the infected
heart [38,39], the mean waiting period of Japanese trans-
plant candidates exceeds 2 years. Therefore, since we need
to treat infections chronically regardless of the causes, we
did not analyze the causes of infection in this observation.
The major limitation of this study was that the inﬂow can-
nula drainage site had been changed from the left atrium to
the left ventricle over the years, and most of the patients
nowadays undergo LVAD surgery with inﬂow cannula drainage
at the left ventricle. The biggest difference between these
two systems may be the bypass ﬂow ratio, and this differ-
ence possibly impacts the survival rate. However, we were
not able to pursue the bypass ﬂow ratio of patients sup-
ported by LVAD with left atrial blood drainage. A difference
in ﬂow ratio between groups A and B could possibly inﬂuence
the analysis of survival. In addition to the difference of ﬂow
ratio and a higher tendency of clot formation in LVAD with
left atrial cannula than that with left ventricular cannula,
Sakamoto [40] reported that LVAD with ventricular cannula
maintained normal cellular anatomy and reserve inotropic
power during support, and patients were exposed to less
elevated afterload compared to LVAD with atrial cannula.
These advantages of ventricular cannula to atrial cannula
could also be a factor contributing to better outcome in
group B than in group A, despite the less favorable preopera-
tive conditions in group B as reﬂected by more deteriorated
renal insufﬁciency and higher BNP level in this group.
Clinical implications
Although extracorporeal LVAD is no longer a ﬁrst-line
mechanical support device in many countries, the main com-
plications are the same as those of new generation devices.
LVAD drainage site could be one of the most important
factors contributing to the long-term survival of patients
on LVAD, which affect the incidence of infection, clot for-
mation, or other complications. However, we did want to
focus on the recent progression in management of LVAD-
related complication in the present manuscript. Our skill
in device management has improved because patients who
await transplants for a mean of over 2 years require inten-
sive care. In addition, the number of patients who require
LVAD as a ‘destination therapy’ is increasing worldwide.
Therefore, the importance of the device itself and the man-
agement skills for long-term use is increasing. In that sense,
the present ﬁndings derived from our observations should
help patients supported by LVAD even with a new generation
device, to be carefully treated in the face of an increasing
incidence of chronic complications such as infection or CVA.ventricular assist device 227
tudy limitations
his is single-center, retrospective analysis of patients sup-
orted by a single device. All patients were on the device as
bridge-to-transplant strategy, therefore the baseline char-
cteristics differ from those of other reported investigations
n the feasibility of long-term support. The patient cohort
as relatively small, and some of our results might be quite
ifferent in a larger population.
onclusion
n conclusion, we showed that the long-term survival of
atients on pulsatile extracorporeal LVAD has improved
ecently due to delicate and timely treatment of LVAD-
elated complications. The management of CVA and SI play
n important role in long-term LVAD support.
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